Gaucher & Pompe Diseases Enzyme Replacement Therapy (ERT) Market
Number of pages: 100 | Report Format: PDF | Published date: May 03, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 6.19 billion |
|
Revenue Forecast in 2031 |
US$ 10.67 billion |
|
CAGR |
6.3% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Indication, Route of Administration, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global Gaucher and Pompe diseases enzyme replacement therapy market was valued at US$ 6.19 billion in 2022 and is expected to register a revenue CAGR of 6.3% to reach US$ 10.67 billion by 2031.
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market Fundamentals
Enzyme replacement treatment (ERT) includes intravenous (IV) infusions to repair the underlying enzyme deficit that causes Gaucher’s illness. Enzyme replacement therapy is commonly used to treat lysosomal storage diseases. ERT compensates for low amounts of glucocerebrosidase (GCase) enzyme with a modified form of the enzyme. This enzyme degrades glucocerebroside, a fatty substance that accumulates in the bodies of Gaucher disease patients.
Many patients receive ERT at infusion centers and specialized medical facilities providing IV infusions. Patients arrive at the infusion center and wait for medical personnel to prepare the drug. The process can take an hour or more, but some institutions will begin preparing when patients arrive.
The global Gaucher and Pompe diseases enzyme replacement therapy industry analysis report comprehensively analyzes the market, with the factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the Gaucher and Pompe diseases enzyme replacement therapy market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments contributing to the growth of Gaucher and Pompe diseases enzyme replacement therapy (ERT). The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other important information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
[8567]
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market Dynamics
One of the key development drivers in this industry is the expanding elderly population. The number of persons suffering from these diseases is predicted to rise significantly, increasing the demand for enzyme replacement therapy. There has also been an increase in the prevalence of Gaucher disease and Pompe disease, which may be regarded as a primary cause of the rising adoption rates.
Increased demand for ERT to enhance the treatment of uncommon illnesses and a rise in government investment in healthcare infrastructure, such as advantageous reimbursement for ERT, drive market expansion. The growth in the availability of enzyme replacement treatments, as well as the increased acceptance of enzyme replacement therapy (ERT) to replace particular faulty enzymes in LSD patients with in vitro generated functioning enzymes, are also influencing the market. Furthermore, increased population, growing awareness, improved healthcare infrastructure, and less stringent guidelines for rare diseases all benefit the Gaucher disease and Pompe enzyme replacement therapy market.
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market Ecosystem
Gaucher and Pompe diseases enzyme replacement therapy market, by Indication
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market, by Route of Administration
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market by Route of Administration
[546856]
The oral administration method is chosen above the other administration routes due to its numerous benefits. These benefits include safety, patient compliance, the convenience of ingesting, pain avoidance, and the ability to accept a wide range of medications. It is the favored method because of its benefits, such as non-invasiveness, patient compliance, and ease of medication delivery. Several factors influence oral drug absorption, including drug solubility, mucosal permeability, and gastrointestinal tract stability. Efforts to overcome these hurdles have centered on understanding the physicochemical, biochemical, metabolic, and biological limitations restricting total medication bioavailability.
The market segmentation sections provide the Gaucher and Pompe diseases enzyme replacement therapy market outlook in terms of the demarcation of different consumer groups. Market segmentation is the split of an industry into subgroups depending on characteristics such as indication and route of administration. Market segmentation data helps organizations understand the preferences and distinctive demands of different customer groups and implement targeted marketing strategies. This data additionally helps in identifying potential Gaucher and Pompe diseases enzyme replacement therapy market demand opportunities.
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market by Region
The United States is expected to dominate the global marketplace in North America. Rising urbanization, expanding economies, and developing healthcare infrastructure drive the Gaucher and Pompe diseases enzyme replacement therapy market in the United States. The increasing technical advancement in healthcare equipment use of Al and Iot for diagnostics is boosting the country's market potential. Healthcare practitioners do medical research by utilizing these cutting-edge technologies. Massive investment, urbanization, and new product releases propel the country's market size forward.
China is expected to have a substantial revenue CAGR. China's Gaucher and Pompe disorders enzyme replacement therapy (ERT) market is fueled by improved healthcare infrastructure, medical facilities, and research and development activities. The country's enzyme replacement therapeutic invention is increasing its massive earnings.
Based on the regions, the global Gaucher and Pompe diseases enzyme replacement therapy market is segmented into:
The industry's regional segmentation provides insights into geographic pockets in terms of Gaucher and Pompe diseases enzyme replacement therapy industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level Gaucher and Pompe Diseases enzyme replacement therapy market overview.
Key Components of the Report
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market Competitive Landscape
The market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on factors such as products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market Strategic Developments
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Enzyme replacement treatment (ERT) includes intravenous (IV) infusions to repair the underlying enzyme deficit that causes Gaucher’s illness. Enzyme replacement therapy is commonly used to treat lysosomal storage diseases. ERT compensates for low amounts of glucocerebrosidase (GCase) enzyme with a modified form of the enzyme.
The total Gaucher and Pompe diseases enzyme replacement therapy market size worldwide in 2022 will be 6.19 billion.
North America will have the largest Gaucher and Pompe diseases enzyme replacement therapy market size during the forecast period from 2023 to 2031.
The revenue CAGR of the global colorectal Gaucher and Pompe diseases enzyme replacement therapy is expected to have 6.3%.
The resultant market size of the Gaucher and Pompe diseases enzyme replacement therapy market in 2031 will be 10.67 billion.
The availability of alternatives to enzyme replacement therapy and reimbursement concerns in some regions are projected to stymie market expansion.
Strategies for marketing used by market participants include partnerships, acquisitions, collaborations, product launches, agreements, and mergers. These players generate the most revenue in the global market through distribution channels and suppliers.
Some prominent market players in the global Gaucher and Pompe diseases enzyme replacement therapy market include Alexion Pharmaceuticals, Inc., Pfizer, and AbbVie Inc.
The oral route of administration has the highest share in the global Gaucher and Pompe diseases enzyme replacement therapy market.
*Insights on financial performance are subject to the availability of information in the public domain